|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinically, the EPHX1 expression in patients with HCC was markedly downregulated.
|
31566711 |
2020 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that EPHX1 genetic polymorphisms were not associated with the risk of HCC.
|
23955801 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There is substantial evidence that mEH polymorphisms interact synergistically with other genes and the environment to modulate risk of HCC.
|
23451147 |
2013 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Arg-His-Arg haplotype of XRCC1 significantly enhanced the risk for hepatitis by 2.8-folds (p = 0.001), but not for HCC (odds ratio = 1.5; p = 0.28). mEPHX haplotypes shared a positive association with HCC risk in India.
|
19754350 |
2009 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In case of mEPHX, R139R imposed a risk factor for HCC with both control (OR = 1.81) and chronic hepatitis-infected (OR = 2.06) subjects.
|
18816171 |
2008 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In case of mEPHX, R139R imposed a risk factor for HCC with both control (OR = 1.81) and chronic hepatitis-infected (OR = 2.06) subjects.
|
18816171 |
2008 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A weak association of the HYL1*2 polymorphism with HCC was observed but did not reach statistical significance.GSTT1 was not associated with HCC.
|
15734960 |
2005 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the GSTT1 and EPHX1 loci did not appear to be related to HCC in the total population of the human study, a polymorphism in GSTA4 was significantly related to risk in the male subset.
|
12907637 |
2003 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition to the tumor size and frequency of local recurrence, our results further indicated that expression of DDH1/2 was correlated with those of cyclooxygenase 2 (COX-2), interleukin-6 (IL-6), microsomal epoxide hydrolase (mEpH) and soluble epoxide hydrolase (sEpH) in HCC patients.
|
12579257 |
2003 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
When mEH genotypes were combined to express a metabolic phenotype, very slow metabolizers were highly prevalent among cirrhotic and HCC patients (18% vs. 3.3% in carriers; P <.001).
|
12085365 |
2002 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
When mEH genotypes were combined to express a metabolic phenotype, very slow metabolizers were highly prevalent among cirrhotic and HCC patients (18% vs. 3.3% in carriers; P <.001).
|
12085365 |
2002 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma.
|
11440964 |
2001 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population.
|
10817627 |
2000 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphic forms of the human EPHX gene have been described that vary in enzymatic activity, and one, Tyr113His, has been associated with hepatocellular carcinoma susceptibility.
|
8944076 |
1996 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1.
|
7892276 |
1995 |